Sharon J Gardiner1, Matthew P Doogue, Mei Zhang, Evan J Begg. 1. Department of Clinical Pharmacology, Christchurch Hospital and Christchurch School of Medicine, Christchurch, New Zealand. sharon.gardiner@cdhb.govt.nz
Abstract
AIMS: To determine the milk-to-plasma (M/P) concentration ratio of celecoxib, and estimate likely infant exposure. METHODS: Blood and milk were sampled for 48 h after oral administration of celecoxib 200 mg to six lactating volunteers. The M/P ratio was derived from the area under the concentration-time curves (0-infinity) and the infant 'dose' estimated from celecoxib concentrations in milk. RESULTS: The median (range) M/P ratio was 0.18 (0.15-0.26). The median (range) infant 'dose' was 0.23% (0.17-0.30%) of the maternal dose, adjusted for weight. CONCLUSION: The relative 'dose' of celecoxib to which infants are exposed via milk is very low, suggesting that breastfeeding during routine dosing would pose minimal risk.
AIMS: To determine the milk-to-plasma (M/P) concentration ratio of celecoxib, and estimate likely infant exposure. METHODS: Blood and milk were sampled for 48 h after oral administration of celecoxib 200 mg to six lactating volunteers. The M/P ratio was derived from the area under the concentration-time curves (0-infinity) and the infant 'dose' estimated from celecoxib concentrations in milk. RESULTS: The median (range) M/P ratio was 0.18 (0.15-0.26). The median (range) infant 'dose' was 0.23% (0.17-0.30%) of the maternal dose, adjusted for weight. CONCLUSION: The relative 'dose' of celecoxib to which infants are exposed via milk is very low, suggesting that breastfeeding during routine dosing would pose minimal risk.
Authors: Karla Esbona; David Inman; Sandeep Saha; Justin Jeffery; Pepper Schedin; Lee Wilke; Patricia Keely Journal: Breast Cancer Res Date: 2016-03-22 Impact factor: 6.466